Impact of dose-capping chemotherapy in concurrent chemoradiotherapy in rectal cancer patients.

Ran YangMoftah YounisKurian JosephSunita GhoshTirath NijjarDiane SeverinKeith TankelYash TamhaneAlysa FairchildJennifer SpratlinKaren MulderNawaid Usmani

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)

Rectal cancer patients treated with dose-capped CRT were at increased risk of disease recurrence. Patients dosed by actual BSA did experience excessive toxicity compared to dose-capped group. We recommend that chemotherapy dose-capping based on BSA should not be practiced in rectal cancer patients undergoing CRT.

Keyphrases

rectal cancer
locally advanced
patients undergoing
squamous cell carcinoma
radiation therapy
end stage renal disease
newly diagnosed
ejection fraction
oxidative stress
prognostic factors
weight gain
atrial fibrillation